Breaking Down Dendreon's European Recommendation
Shares of Dendreon popped nearly 10% Friday morning on news coming out of Europe. The CHMP, which is Europe's version of an FDA advisory committee, recommended that the biotech's prostate cancer vaccine, Provenge, be approved.
In this video, health care analyst David Williamson discusses what this recommendation means for Provenge's chances of approval, Dendreon's likely next move, and whether this will serve as a catalyst for shares going forward.
Rising health care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health care system -- and how to potentially profit from this trend -- click here for free, immediate access.
Follow David on Twitter: @MotleyDavid.
The article Breaking Down Dendreon's European Recommendation originally appeared on Fool.com.David Williamson owns shares of Johnson & Johnson. Follow David on Twitter: @MotleyDavid. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.